Summit Therapeutics SMMT 深 滬
等待開盤 10-08 09:30:00 美东时间
17.905
+0.595
+3.44%
華盛通- 最 高18.328
- 今 開17.13
- 成交量 573.94万股
- 最 低 16.98
- 昨 收 17.31
- 總市值 142.84亿
- 52周最高 29.23
- 市盈率 靜 --
- 換手率 0.72%
- 52周最低 12.07
- 委 比 -81.16%
- 總股本 7.98亿
- 歷史最高 36.91
- 量 比 1.11
- 振 幅 7.79%
- 歷史最低 0.66
- 每 手 1
- 風險率 2.58%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AstraZeneca CEO Soriot says drugmaker can grow without big acquisition
AstraZeneca (AZN) CEO Pascal Soriot said that the British drugmaker can continue to grow past the end of the decade without engaging in a major acquisition. "We absolutely have what we need," he told ...
10-06 05:27
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership
AstraZeneca PLC (NASDAQ:AZN) and Daiichi Sankyo Co., Ltd.(OTC:DSNKY) said Thursday they entered a clinical collaboration with Summit Therapeutics Inc. (NASDAQ:SMMT) to test a new cancer-drug combination across several tumor types. The companies will evaluate AstraZeneca and Daiichi Sankyo’s Datroway...
10-02 21:28
Robinhood Traders Just Went on Their Biggest Buying Binge Ever
Robinhood Markets, Inc‘s (NASDAQ:HOOD) retail crowd is buying the dips at a record pace. According to the company’s EntryPoint newsletter, retail traders on the platform made their highest-ever five-day net purchases of individual stocks. The trend marks a turnaround from last Wednesday’s and Monday...
10-02 01:43
Summit Therapeutics Stock Climbs Wednesday: What's Happening?
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) moved higher in Wednesday afternoon trading, extending gains from the previous session following a landmark $2 billion strategic equity investment from pharmaceutical titan AstraZeneca to accelerate the clinical development of ivonescimab. Here’s what...
10-01 04:16
野村：予康方生物目标价138.29港元以及“买入”评级
9月30日，野村发布研报称，予康方生物（09926.HK）目标价138.29港元以及“买入”评级。康方生物及其海外合作伙伴Summit Therapeutic...
09-30 15:08
美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
Citigroup Maintains Buy on Summit Therapeutics, Raises Price Target to $43
Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $40 to $43.
09-30 01:52
AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC
AstraZeneca has submitted an NDA to the US FDA seeking approval of a combination regimen of savolitinib plus Tagrisso (osimertinib) as a second-line therapy for locally advanced or metastatic non-smal...
09-30 01:28
美股异动｜Summit Therapeutics大涨超23%，获阿斯利康20亿美元投资
Summit Therapeutics(SMMT.US)盘初大涨超23%，最高触及19.07美元。消息面上，阿斯利康同意向临床阶段肿瘤公司Summit The...
09-29 21:58
AstraZeneca Invests in Summit Therapeutics after Year of Speculation
AstraZeneca Plc (NYSE:AZN) on Tuesday agreed to invest $2 billion in newly issued equity in Summit Therapeutics Inc. (NASDAQ:SMMT) to accelerate the development of ivonescimab in combination with antibody-drug conjugates (ADCs) across tumor types. In July 2025, media reports circulated related to th...
09-29 21:12
